US5817661A
(en)
|
1991-12-06 |
1998-10-06 |
Hoechst Marion Roussel, Inc. |
Trans cyclopentanyl purine analogs useful as immunosuppressants
|
US5723466A
(en)
*
|
1991-12-06 |
1998-03-03 |
Hoechst Marion Roussel, Inc. |
Trans cyclopentanyl purine analogs useful as immunosuppressants
|
US5817660A
(en)
*
|
1991-12-06 |
1998-10-06 |
Hoechst Marion Roussel, Inc. |
Trans cyclopentanyl purine analogs useful as immunosuppressants
|
US5817672A
(en)
*
|
1991-12-06 |
1998-10-06 |
Hoechst Marion Roussel, Inc. |
Trans cyclopentanyl purine analogs useful as immunosuppressants
|
US5648516A
(en)
*
|
1994-07-20 |
1997-07-15 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
US6011039A
(en)
*
|
1996-03-21 |
2000-01-04 |
Banyu Pharmaceutical Co., Ltd. |
Aminopyridine derivatives
|
US5741908A
(en)
|
1996-06-21 |
1998-04-21 |
Minnesota Mining And Manufacturing Company |
Process for reparing imidazoquinolinamines
|
ES2290969T3
(es)
|
1996-10-25 |
2008-02-16 |
Minnesota Mining And Manufacturing Company |
Compuestos modificadores de la respuesta inmune para el tratamiento de enfermedades mediadas por th2 y relacionadas.
|
UA67760C2
(uk)
|
1997-12-11 |
2004-07-15 |
Міннесота Майнінг Енд Мануфакчурінг Компані |
Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
|
US6110929A
(en)
|
1998-07-28 |
2000-08-29 |
3M Innovative Properties Company |
Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
|
US6518280B2
(en)
*
|
1998-12-11 |
2003-02-11 |
3M Innovative Properties Company |
Imidazonaphthyridines
|
US6486168B1
(en)
|
1999-01-08 |
2002-11-26 |
3M Innovative Properties Company |
Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
|
US20020058674A1
(en)
|
1999-01-08 |
2002-05-16 |
Hedenstrom John C. |
Systems and methods for treating a mucosal surface
|
SK287112B6
(sk)
|
1999-01-08 |
2009-12-07 |
3M Innovative Properties Company |
Použitie zlúčeniny modifikujúcej imunitnú odpoveď pri liečení cervikálnej dysplázie
|
US6558951B1
(en)
*
|
1999-02-11 |
2003-05-06 |
3M Innovative Properties Company |
Maturation of dendritic cells with immune response modifying compounds
|
US6541485B1
(en)
|
1999-06-10 |
2003-04-01 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6331539B1
(en)
*
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
US6756382B2
(en)
*
|
1999-06-10 |
2004-06-29 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6573273B1
(en)
|
1999-06-10 |
2003-06-03 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6451810B1
(en)
|
1999-06-10 |
2002-09-17 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6916925B1
(en)
|
1999-11-05 |
2005-07-12 |
3M Innovative Properties Co. |
Dye labeled imidazoquinoline compounds
|
US6376669B1
(en)
|
1999-11-05 |
2002-04-23 |
3M Innovative Properties Company |
Dye labeled imidazoquinoline compounds
|
JP3436512B2
(ja)
*
|
1999-12-28 |
2003-08-11 |
株式会社デンソー |
アクセル装置
|
US6894060B2
(en)
|
2000-03-30 |
2005-05-17 |
3M Innovative Properties Company |
Method for the treatment of dermal lesions caused by envenomation
|
US6677348B2
(en)
*
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Aryl ether substituted imidazoquinolines
|
UA74852C2
(en)
|
2000-12-08 |
2006-02-15 |
3M Innovative Properties Co |
Urea-substituted imidazoquinoline ethers
|
CA2598144A1
(en)
*
|
2000-12-08 |
2006-08-31 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
US6667312B2
(en)
*
|
2000-12-08 |
2003-12-23 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6664260B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Heterocyclic ether substituted imidazoquinolines
|
UA74593C2
(en)
*
|
2000-12-08 |
2006-01-16 |
3M Innovative Properties Co |
Substituted imidazopyridines
|
US6677347B2
(en)
*
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
US6660735B2
(en)
*
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Urea substituted imidazoquinoline ethers
|
US20020110840A1
(en)
*
|
2000-12-08 |
2002-08-15 |
3M Innovative Properties Company |
Screening method for identifying compounds that selectively induce interferon alpha
|
US6545016B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Amide substituted imidazopyridines
|
US6664265B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US6660747B2
(en)
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US20020107262A1
(en)
*
|
2000-12-08 |
2002-08-08 |
3M Innovative Properties Company |
Substituted imidazopyridines
|
US6525064B1
(en)
|
2000-12-08 |
2003-02-25 |
3M Innovative Properties Company |
Sulfonamido substituted imidazopyridines
|
US6664264B2
(en)
*
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6545017B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Urea substituted imidazopyridines
|
US7226928B2
(en)
*
|
2001-06-15 |
2007-06-05 |
3M Innovative Properties Company |
Methods for the treatment of periodontal disease
|
MXPA04001972A
(es)
*
|
2001-08-30 |
2005-02-17 |
3M Innovative Properties Co |
Metodos para hacer madurar celulas dendricas plasmacitoide utilizando moleculas modificadoras de respuesta enmune.
|
WO2003043572A2
(en)
*
|
2001-11-16 |
2003-05-30 |
3M Innovative Properties Company |
Methods and compositions related to irm compounds and toll-like receptor pathways
|
AU2004220469B2
(en)
*
|
2001-11-29 |
2010-07-29 |
3M Innovative Properties Company |
Methods of improving skin quality
|
RU2327460C2
(ru)
*
|
2001-11-29 |
2008-06-27 |
3М Инновейтив Пропертиз Компани |
Фармацевтические составы, содержащие иммуномодулятор
|
CA2365732A1
(en)
*
|
2001-12-20 |
2003-06-20 |
Ibm Canada Limited-Ibm Canada Limitee |
Testing measurements
|
US6677349B1
(en)
|
2001-12-21 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
MXPA04008023A
(es)
*
|
2002-02-22 |
2004-11-26 |
3M Innovative Properties Co |
Metodo para reducir y tratar inmunosupresion inducida por uvb.
|
CA2484044A1
(en)
*
|
2002-03-19 |
2003-10-02 |
Powdermed Limited |
Imidazoquinolineamines as adjuvants in hiv dna vaccination
|
DE60335350D1
(de)
*
|
2002-03-19 |
2011-01-27 |
Powderject Res Ltd |
Adjuvantien für dns impstoffe basierend auf imidazochinoline
|
ES2734652T3
(es)
|
2002-04-04 |
2019-12-11 |
Zoetis Belgium S A |
Oligorribonucleótidos inmunoestimulantes que contienen G y U
|
AU2003233519A1
(en)
|
2002-05-29 |
2003-12-19 |
3M Innovative Properties Company |
Process for imidazo(4,5-c)pyridin-4-amines
|
CA2488801A1
(en)
|
2002-06-07 |
2003-12-18 |
3M Innovative Properties Company |
Ether substituted imidazopyridines
|
GB0215293D0
(en)
|
2002-07-03 |
2002-08-14 |
Rega Foundation |
Viral inhibitors
|
DE60335010D1
(de)
|
2002-08-15 |
2010-12-30 |
3M Innovative Properties Co |
Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort
|
JP2006503068A
(ja)
*
|
2002-09-26 |
2006-01-26 |
スリーエム イノベイティブ プロパティズ カンパニー |
1h−イミダゾダイマー
|
AU2003270701B2
(en)
|
2002-10-31 |
2009-11-12 |
Amgen Inc. |
Antiinflammation agents
|
WO2004053057A2
(en)
*
|
2002-12-11 |
2004-06-24 |
3M Innovative Properties Company |
Gene expression systems and recombinant cell lines
|
AU2003287316A1
(en)
*
|
2002-12-11 |
2004-06-30 |
3M Innovative Properties Company |
Assays relating to toll-like receptor activity
|
AU2003301052A1
(en)
|
2002-12-20 |
2004-07-22 |
3M Innovative Properties Company |
Aryl / hetaryl substituted imidazoquinolines
|
JP2006512391A
(ja)
*
|
2002-12-30 |
2006-04-13 |
スリーエム イノベイティブ プロパティズ カンパニー |
組み合わせ免疫賦活薬
|
JP2006517974A
(ja)
*
|
2003-02-13 |
2006-08-03 |
スリーエム イノベイティブ プロパティズ カンパニー |
Irm化合物およびトル様受容体8に関する方法および組成物
|
EP1599726A4
(de)
*
|
2003-02-27 |
2009-07-22 |
3M Innovative Properties Co |
Selektive modulation von tlr-vermittelter biologischer aktivität
|
JP2006519866A
(ja)
|
2003-03-04 |
2006-08-31 |
スリーエム イノベイティブ プロパティズ カンパニー |
Uv誘発性の表皮の新形成の予防的治療
|
US7163947B2
(en)
*
|
2003-03-07 |
2007-01-16 |
3M Innovative Properties Company |
1-Amino 1H-imidazoquinolines
|
US20040176367A1
(en)
*
|
2003-03-07 |
2004-09-09 |
3M Innovative Properties Company |
1-Amino 1H-imidazoquinolines
|
CA2518082C
(en)
*
|
2003-03-13 |
2013-02-12 |
3M Innovative Properties Company |
Methods for diagnosing skin lesions
|
AU2004220465A1
(en)
*
|
2003-03-13 |
2004-09-23 |
3M Innovative Properties Company |
Method of tattoo removal
|
US20040192585A1
(en)
*
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Treatment for basal cell carcinoma
|
EP2258365B1
(de)
|
2003-03-28 |
2013-05-29 |
Novartis Vaccines and Diagnostics, Inc. |
Verwendung von organischen verbindungen zur immunstärkung
|
US7923560B2
(en)
*
|
2003-04-10 |
2011-04-12 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
US20040265351A1
(en)
*
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
WO2004096144A2
(en)
*
|
2003-04-28 |
2004-11-11 |
3M Innovative Properties Company |
Compositions and methods for induction of opioid receptors
|
US20050032829A1
(en)
*
|
2003-06-06 |
2005-02-10 |
3M Innovative Properties Company |
Process for imidazo[4,5-c]pyridin-4-amines
|
WO2004110991A2
(en)
*
|
2003-06-06 |
2004-12-23 |
3M Innovative Properties Company |
PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
|
CA2534042A1
(en)
*
|
2003-07-31 |
2005-02-10 |
3M Innovative Properties Company |
Compositions for encapsulation and controlled release
|
CN1852711A
(zh)
*
|
2003-08-05 |
2006-10-25 |
3M创新有限公司 |
使用免疫响应调节化合物的传染病预防
|
TW200524927A
(en)
|
2003-08-12 |
2005-08-01 |
3M Innovative Properties Co |
Hydroxylamine substituted imidazo-containing compounds
|
WO2005018555A2
(en)
*
|
2003-08-14 |
2005-03-03 |
3M Innovative Properties Company |
Lipid-modified immune response modifiers
|
EP1658035A4
(de)
|
2003-08-25 |
2007-08-22 |
3M Innovative Properties Co |
Abgabe von die immunantwort modifizierenden verbindungen
|
AU2004266162A1
(en)
*
|
2003-08-25 |
2005-03-03 |
3M Innovative Properties Company |
Immunostimulatory combinations and treatments
|
WO2005020999A1
(en)
|
2003-08-27 |
2005-03-10 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted imidazoquinolines
|
MXPA06002408A
(es)
*
|
2003-09-02 |
2006-06-20 |
3M Innovative Properties Co |
Metodos relacionados al tratamiento de condiciones asociadas a la mucosa.
|
JP2007504269A
(ja)
*
|
2003-09-05 |
2007-03-01 |
スリーエム イノベイティブ プロパティズ カンパニー |
Cd5+b細胞リンパ腫の治療方法
|
US20050059072A1
(en)
*
|
2003-09-17 |
2005-03-17 |
3M Innovative Properties Company |
Selective modulation of TLR gene expression
|
CA2536530A1
(en)
*
|
2003-10-01 |
2005-04-14 |
Taro Pharmaceuticals U.S.A., Inc. |
Method of preparing 4-amino-1h-imidazo(4,5-c)quinolines and acid addition salts thereof
|
US20090075980A1
(en)
*
|
2003-10-03 |
2009-03-19 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and Analogs Thereof
|
KR101154101B1
(ko)
|
2003-10-03 |
2012-06-11 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
알콕시 치환된 이미다조퀴놀린
|
SG149829A1
(en)
|
2003-10-03 |
2009-02-27 |
3M Innovative Properties Co |
Pyrazolopyridines and analogs thereof
|
US7544697B2
(en)
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
CA2543685A1
(en)
*
|
2003-10-31 |
2005-05-12 |
3M Innovative Properties Company |
Neutrophil activation by immune response modifier compounds
|
CN1906192A
(zh)
|
2003-11-14 |
2007-01-31 |
3M创新有限公司 |
羟胺取代的咪唑环化合物
|
US7897767B2
(en)
*
|
2003-11-14 |
2011-03-01 |
3M Innovative Properties Company |
Oxime substituted imidazoquinolines
|
CA2547020C
(en)
|
2003-11-25 |
2014-03-25 |
3M Innovative Properties Company |
1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
|
AU2004293096A1
(en)
*
|
2003-11-25 |
2005-06-09 |
3M Innovative Properties Company |
Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
JP2007513165A
(ja)
*
|
2003-12-02 |
2007-05-24 |
スリーエム イノベイティブ プロパティズ カンパニー |
Irm化合物を含む併用薬および治療方法
|
CA2549216A1
(en)
|
2003-12-04 |
2005-08-25 |
3M Innovative Properties Company |
Sulfone substituted imidazo ring ethers
|
US7888349B2
(en)
|
2003-12-29 |
2011-02-15 |
3M Innovative Properties Company |
Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds
|
WO2005066170A1
(en)
|
2003-12-29 |
2005-07-21 |
3M Innovative Properties Company |
Arylalkenyl and arylalkynyl substituted imidazoquinolines
|
EP1699788A2
(de)
|
2003-12-30 |
2006-09-13 |
3M Innovative Properties Company |
Imidazochinolinyl-, imidazopyridinyl- und imidazonaphthyridinylsulfonamide
|
US20050239735A1
(en)
*
|
2003-12-30 |
2005-10-27 |
3M Innovative Properties Company |
Enhancement of immune responses
|
JP4991520B2
(ja)
*
|
2004-03-15 |
2012-08-01 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答調節剤製剤および方法
|
TW200612932A
(en)
|
2004-03-24 |
2006-05-01 |
3M Innovative Properties Co |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
JP2007532572A
(ja)
*
|
2004-04-09 |
2007-11-15 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫反応調整剤を送達させるための方法、組成物および調製物
|
BRPI0510430A
(pt)
*
|
2004-04-28 |
2007-10-30 |
3M Innovative Properties Co |
composições e métodos para vacinação mucosal
|
EP2811027A1
(de)
|
2004-05-21 |
2014-12-10 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus-Vektoren für RSV- und PIV-Impfstoffe
|
US20050267145A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
US20080015184A1
(en)
*
|
2004-06-14 |
2008-01-17 |
3M Innovative Properties Company |
Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
|
US8017779B2
(en)
|
2004-06-15 |
2011-09-13 |
3M Innovative Properties Company |
Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
US8026366B2
(en)
|
2004-06-18 |
2011-09-27 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
US7915281B2
(en)
|
2004-06-18 |
2011-03-29 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
|
WO2006038923A2
(en)
|
2004-06-18 |
2006-04-13 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
WO2006028545A2
(en)
*
|
2004-06-18 |
2006-03-16 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
WO2006009832A1
(en)
*
|
2004-06-18 |
2006-01-26 |
3M Innovative Properties Company |
Substituted imidazo ring systems and methods
|
US8541438B2
(en)
|
2004-06-18 |
2013-09-24 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
EP2277595A3
(de)
|
2004-06-24 |
2011-09-28 |
Novartis Vaccines and Diagnostics, Inc. |
Verbindungen zur Immunopotenzierung
|
WO2006115509A2
(en)
|
2004-06-24 |
2006-11-02 |
Novartis Vaccines And Diagnostics Inc. |
Small molecule immunopotentiators and assays for their detection
|
BRPI0513811A
(pt)
*
|
2004-07-27 |
2008-07-15 |
Gilead Sciences Inc |
imidazo [4,5-d] pirimidinas, seus usos e processos de preparação
|
EP1786450A4
(de)
*
|
2004-08-27 |
2009-11-11 |
3M Innovative Properties Co |
Hiv-immunstimulatorische zusammensetzungen
|
US20090270443A1
(en)
*
|
2004-09-02 |
2009-10-29 |
Doris Stoermer |
1-amino imidazo-containing compounds and methods
|
AU2005282523A1
(en)
|
2004-09-02 |
2006-03-16 |
3M Innovative Properties Company |
2-amino 1H imidazo ring systems and methods
|
ATE555786T1
(de)
*
|
2004-09-02 |
2012-05-15 |
3M Innovative Properties Co |
1-alkoxy 1h-imidazo-ringsysteme und verfahren
|
WO2006029223A2
(en)
*
|
2004-09-08 |
2006-03-16 |
Children's Medical Center Corporation |
Method for stimulating the immune response of newborns
|
US20080213308A1
(en)
*
|
2004-09-14 |
2008-09-04 |
Nicholas Valiante |
Imidazoquinoline Compounds
|
US20070243215A1
(en)
*
|
2004-10-08 |
2007-10-18 |
Miller Richard L |
Adjuvant for Dna Vaccines
|
EP1819364A4
(de)
*
|
2004-12-08 |
2010-12-29 |
3M Innovative Properties Co |
Immunmodulatorische zusammensetzungen, kombinationen und verfahren
|
US8080560B2
(en)
*
|
2004-12-17 |
2011-12-20 |
3M Innovative Properties Company |
Immune response modifier formulations containing oleic acid and methods
|
JP5543068B2
(ja)
*
|
2004-12-30 |
2014-07-09 |
スリーエム イノベイティブ プロパティズ カンパニー |
キラル縮合[1,2]イミダゾ[4,5−c]環状化合物
|
US8436176B2
(en)
*
|
2004-12-30 |
2013-05-07 |
Medicis Pharmaceutical Corporation |
Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
|
AU2005321912B2
(en)
*
|
2004-12-30 |
2012-04-05 |
3M Innovative Properties Company |
Treatment for cutaneous metastases
|
CA2594674C
(en)
|
2004-12-30 |
2016-05-17 |
3M Innovative Properties Company |
Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
|
WO2006073939A2
(en)
*
|
2004-12-30 |
2006-07-13 |
Takeda Pharmaceutical Company Limited |
1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate
|
WO2006084251A2
(en)
|
2005-02-04 |
2006-08-10 |
Coley Pharmaceutical Group, Inc. |
Aqueous gel formulations containing immune reponse modifiers
|
EP1846419B1
(de)
|
2005-02-09 |
2014-04-16 |
3M Innovative Properties Company |
Alkoxysubstituierte Thiazolochinoline und Thiazolonaphthyridine
|
AU2006338521A1
(en)
|
2005-02-09 |
2007-10-11 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
|
WO2006091394A2
(en)
|
2005-02-11 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Substituted imidazoquinolines and imidazonaphthyridines
|
WO2006086634A2
(en)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
|
DK1858920T3
(en)
|
2005-02-18 |
2016-02-29 |
Glaxosmithkline Biolog Sa |
PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS / SEPSIS-ASSOCIATED ESCHERICHIA COLI
|
ATE552267T1
(de)
|
2005-02-18 |
2012-04-15 |
Novartis Vaccines & Diagnostic |
Immungene von uropathogenen escherichia coli
|
WO2006091647A2
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Method of preferentially inducing the biosynthesis of interferon
|
JP2008531568A
(ja)
|
2005-02-23 |
2008-08-14 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
ヒドロキシアルキルで置換されたイミダゾナフチリジン
|
US8178677B2
(en)
|
2005-02-23 |
2012-05-15 |
3M Innovative Properties Company |
Hydroxyalkyl substituted imidazoquinolines
|
WO2006091567A2
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazoquinoline compounds and methods
|
RU2007137960A
(ru)
|
2005-03-14 |
2009-04-20 |
Меда Аб (Se) |
СПОСОБ ЛЕЧЕНИЯ АКТИНИЧЕСКОГО КЕРАТОЗА (ВАРИАНТЫ) И 2-МЕТИЛ-1-(2-МЕТИЛПРОПИЛ)-1Н-ИМИДАЗО[4,5-c]]1,5]НАФТИРИДИН-4-АМИН В КАЧЕСТВЕ СРЕДСТВА ЛЕЧЕНИЯ АКТИНИЧЕСКОГО КЕРАТОЗА
|
AU2006232377A1
(en)
|
2005-04-01 |
2006-10-12 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridine-1,4-diamines and analogs thereof
|
CA2602590A1
(en)
|
2005-04-01 |
2006-10-12 |
Coley Pharmaceutical Group, Inc. |
1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
|
JP2008539252A
(ja)
|
2005-04-25 |
2008-11-13 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫活性化組成物
|
JP2009501546A
(ja)
|
2005-07-18 |
2009-01-22 |
ノバルティス アーゲー |
Hcv複製についての小動物モデル
|
KR20080031496A
(ko)
*
|
2005-09-02 |
2008-04-08 |
화이자 인코포레이티드 |
히드록시 치환된 1h-이미다조피리딘 및 방법
|
BRPI0615788A2
(pt)
|
2005-09-09 |
2011-05-24 |
Coley Pharm Group Inc |
derivados de amida e carbamato de n-{2-[4-amino (etoximetil)-1h-imidazo [4,5-c] quinolin-1-il]-1,1-dimetiletil} metanossulfonamida, composição farmacêutica destes e seus usos
|
ZA200803029B
(en)
*
|
2005-09-09 |
2009-02-25 |
Coley Pharm Group Inc |
Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
|
US8889154B2
(en)
|
2005-09-15 |
2014-11-18 |
Medicis Pharmaceutical Corporation |
Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
|
EP2357000A1
(de)
|
2005-10-18 |
2011-08-17 |
Novartis Vaccines and Diagnostics, Inc. |
Mukosale und systemische Immunisierungen mit Alphavirus-Replikonpartikeln
|
JP2009514850A
(ja)
|
2005-11-04 |
2009-04-09 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン
|
KR20080083270A
(ko)
|
2005-11-04 |
2008-09-17 |
콜레이 파마시티컬 그룹, 인코포레이티드 |
하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법
|
JP2009514839A
(ja)
|
2005-11-04 |
2009-04-09 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
|
ES2792398T3
(es)
|
2005-11-04 |
2020-11-11 |
Seqirus Uk Ltd |
Vacunas adyuvantadas con antígenos de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
|
EP1951299B1
(de)
|
2005-11-04 |
2012-01-04 |
Novartis Vaccines and Diagnostics S.r.l. |
Grippeimpfstoffe mit kombinationen aus teilchenförmigen adjuvantien und immunverstärkern
|
EP1969001A2
(de)
|
2005-11-22 |
2008-09-17 |
Novartis Vaccines and Diagnostics, Inc. |
Norovirus- und sapovirus-antigene
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
WO2007085969A2
(en)
|
2006-01-27 |
2007-08-02 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg |
Influenza vaccines containing hemagglutinin and matrix proteins
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
WO2007100634A2
(en)
|
2006-02-22 |
2007-09-07 |
3M Innovative Properties Company |
Immune response modifier conjugates
|
WO2007106854A2
(en)
|
2006-03-15 |
2007-09-20 |
Coley Pharmaceutical Group, Inc. |
Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
|
EP2357184B1
(de)
|
2006-03-23 |
2015-02-25 |
Novartis AG |
Imidazochinoxalinverbindungen als Immunmodulatoren
|
CA2647100A1
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Methods for the preparation of imidazole-containing compounds
|
WO2007109812A2
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
EP2004226A1
(de)
|
2006-03-24 |
2008-12-24 |
Novartis Vaccines and Diagnostics GmbH & Co. KG |
Lagerung von grippeimpfstoffen ohne kühlung
|
SG173336A1
(en)
|
2006-03-31 |
2011-08-29 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
AR060358A1
(es)
*
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
ATE522541T1
(de)
|
2006-06-09 |
2011-09-15 |
Novartis Ag |
Bakterielle adhäsine konformere
|
US7906506B2
(en)
|
2006-07-12 |
2011-03-15 |
3M Innovative Properties Company |
Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
AU2007279376B2
(en)
*
|
2006-07-31 |
2012-09-06 |
Wirra Ip Pty Ltd |
Immune response modifier compositions and methods
|
CA2659552A1
(en)
|
2006-08-16 |
2008-02-21 |
Novartis Ag |
Immunogens from uropathogenic escherichia coli
|
WO2008030511A2
(en)
|
2006-09-06 |
2008-03-13 |
Coley Pharmaceuticial Group, Inc. |
Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
|
US20100010199A1
(en)
|
2006-09-11 |
2010-01-14 |
Novartis Ag |
Making influenza virus vaccines without using eggs
|
WO2008068631A2
(en)
|
2006-12-06 |
2008-06-12 |
Novartis Ag |
Vaccines including antigen from four strains of influenza virus
|
US20080149123A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
US20100028420A1
(en)
*
|
2006-12-22 |
2010-02-04 |
3M Innovative Properties Company |
Controlled release composition and process
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
KR101313804B1
(ko)
*
|
2007-03-20 |
2013-10-01 |
쿠리스 인코퍼레이션 |
Hsp90 억제제로서의 융합된 아미노 피리딘
|
PL2185191T3
(pl)
|
2007-06-27 |
2013-02-28 |
Novartis Ag |
Szczepionki przeciwko grypie o małej zawartości dodatków
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
JP5653215B2
(ja)
|
2007-09-12 |
2015-01-14 |
ノバルティス アーゲー |
Gas57変異体抗原およびgas57抗体
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
UY31545A1
(es)
|
2007-12-20 |
2009-08-03 |
|
Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones
|
BRPI0821240B8
(pt)
|
2007-12-21 |
2022-10-04 |
Novartis Ag |
formas mutantes de estreptolisina o
|
NZ587798A
(en)
|
2008-03-18 |
2013-06-28 |
Novartis Ag |
Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer
|
US8585505B2
(en)
|
2008-12-15 |
2013-11-19 |
Tetris Online, Inc. |
Inter-game interactive hybrid asynchronous computer game infrastructure
|
US8465751B2
(en)
|
2009-01-12 |
2013-06-18 |
Novartis Ag |
Cna—B domain antigens in vaccines against gram positive bacteria
|
JP2012519482A
(ja)
|
2009-03-06 |
2012-08-30 |
ノバルティス アーゲー |
クラミジア抗原
|
PL2411521T3
(pl)
|
2009-03-25 |
2015-08-31 |
Univ Texas |
Kompozycje do stymulacji wrodzonej odporności immunologicznej na patogeny u ssaków
|
EP2419129A2
(de)
|
2009-04-14 |
2012-02-22 |
Novartis AG |
Zusammensetzungen zur immunisierung gegen staphylococcus aerus
|
FR2949344A1
(fr)
|
2009-04-27 |
2011-03-04 |
Novartis Ag |
Vaccins de protection contre la grippe
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
AR077757A1
(es)
|
2009-07-15 |
2011-09-21 |
Novartis Ag |
Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion
|
EP2464658B1
(de)
|
2009-07-16 |
2014-10-01 |
Novartis AG |
Detoxifizierte escherichia coli immunogene
|
US20110033515A1
(en)
*
|
2009-08-04 |
2011-02-10 |
Rst Implanted Cell Technology |
Tissue contacting material
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
US9597326B2
(en)
|
2010-04-13 |
2017-03-21 |
Glaxosmithkline Biologicals Sa |
Benzonapthyridine compositions and uses thereof
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
PL2606047T3
(pl)
|
2010-08-17 |
2017-07-31 |
3M Innovative Properties Company |
Kompozycje, preparaty i sposoby obejmujące lipidowane związki modyfikujące odpowiedź immunologiczną
|
EP4144368A1
(de)
|
2011-01-26 |
2023-03-08 |
GlaxoSmithKline Biologicals S.A. |
Rsv-immunisierungstherapie
|
AU2012213080B2
(en)
|
2011-01-31 |
2014-03-27 |
Novartis Ag |
Novel heterocyclic derivatives
|
ES2782119T3
(es)
|
2011-05-13 |
2020-09-10 |
Glaxosmithkline Biologicals Sa |
Antígenos de F de prefusión del VRS
|
CA2838158C
(en)
|
2011-06-03 |
2019-07-16 |
3M Innovative Properties Company |
Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
|
MX355623B
(es)
|
2011-06-03 |
2018-04-25 |
3M Innovative Properties Co |
Hidrazino-1h-imidazoquinolin-4-aminas y conjugados elaborados a partir de las mismas.
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
CA2841047A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
US20130023736A1
(en)
|
2011-07-21 |
2013-01-24 |
Stanley Dale Harpstead |
Systems for drug delivery and monitoring
|
KR20140090218A
(ko)
|
2011-10-28 |
2014-07-16 |
노파르티스 아게 |
신규 퓨린 유도체 및 질환의 치료에서의 그의 용도
|
AU2012335208B2
(en)
|
2011-11-07 |
2017-08-31 |
Glaxosmithkline Biologicals S.A. |
Carrier molecule comprising a spr0096 and a spr2021 antigen
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
SG11201406592QA
(en)
|
2012-05-04 |
2014-11-27 |
Pfizer |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
NZ700924A
(en)
|
2012-05-16 |
2016-02-26 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
JP2015522580A
(ja)
|
2012-07-06 |
2015-08-06 |
ノバルティス アーゲー |
免疫学的組成物およびその使用
|
DK2941233T3
(da)
|
2013-01-07 |
2020-10-19 |
Univ Pennsylvania |
Sammensætninger og fremgangsmåder til behandling af kutant T-celle-lymfom
|
EP3632458A1
(de)
|
2013-07-26 |
2020-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verbindungen und pharmazeutische zusammensetzungen zur behandlung von bakterieninfektionen
|
WO2015023958A1
(en)
*
|
2013-08-15 |
2015-02-19 |
The University Of Kansas |
Toll-like receptor agonists
|
AU2014306417C1
(en)
|
2013-08-16 |
2019-07-25 |
Memorial Sloan-Kettering Cancer Center |
Selective Grp94 inhibitors and uses thereof
|
JP6446054B2
(ja)
|
2013-11-05 |
2018-12-26 |
スリーエム・イノベイティブ・プロパティーズ・カンパニー |
ゴマ油ベースの注射製剤
|
EP2870974A1
(de)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella-Konjugatimpfstoffe
|
MX2016007376A
(es)
|
2013-12-06 |
2017-05-11 |
Novartis Ag |
Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa.
|
US10421971B2
(en)
|
2014-01-15 |
2019-09-24 |
The University Of Chicago |
Anti-tumor therapy
|
EA037818B1
(ru)
|
2014-03-26 |
2021-05-25 |
Глаксосмитклайн Байолоджикалс С.А. |
Мутантные стафилококковые антигены
|
WO2016044839A2
(en)
|
2014-09-19 |
2016-03-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
|
CN108026092B
(zh)
|
2015-08-31 |
2021-01-26 |
3M创新有限公司 |
胍取代的咪唑并[4,5-c]环化合物
|
CN107922416B
(zh)
|
2015-08-31 |
2021-07-02 |
3M创新有限公司 |
含有取代的胍基团的咪唑并[4,5-c]环化合物
|
WO2017059280A1
(en)
|
2015-10-02 |
2017-04-06 |
The University Of North Carolina At Chapel Hill |
Novel pan-tam inhibitors and mer/axl dual inhibitors
|
AU2016347881A1
(en)
|
2015-11-02 |
2018-05-10 |
Novartis Ag |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
WO2017200957A1
(en)
|
2016-05-16 |
2017-11-23 |
Infectious Disease Research Institute |
Pegylated liposomes and methods of use
|
JP7195148B2
(ja)
|
2016-05-16 |
2022-12-23 |
アクセス ツー アドバンスト ヘルス インスティチュート |
Tlrアゴニストを含有する製剤及び使用方法
|
JP7010286B2
(ja)
|
2016-08-26 |
2022-01-26 |
スリーエム イノベイティブ プロパティズ カンパニー |
グアニジノ基で置換された縮合[1,2]イミダゾ[4,5-c]環状化合物
|
CN110121335A
(zh)
|
2016-08-30 |
2019-08-13 |
达纳-法伯癌症研究所股份有限公司 |
药物递送组合物及其用途
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
BR112019009469A2
(pt)
|
2016-11-09 |
2019-07-30 |
Pulmotect Inc |
métodos e composições para a modulação imunológica adaptativa
|
WO2018160552A1
(en)
|
2017-03-01 |
2018-09-07 |
3M Innovative Properties Company |
IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING GUANIDINE SUBSTITUTED BENZAMIDE GROUPS
|
AR111760A1
(es)
|
2017-05-19 |
2019-08-14 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
|
EP4257198A3
(de)
|
2017-08-22 |
2023-10-18 |
Dynavax Technologies Corporation |
Alkylkettenmodifizierte imidazochinolin-derivate als tlr7/8-agonisten und verwendungen davon
|
WO2019099412A1
(en)
|
2017-11-14 |
2019-05-23 |
Dynavax Technologies Corporation |
Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof
|
US11306083B2
(en)
|
2017-12-20 |
2022-04-19 |
3M Innovative Properties Company |
Amide substituted imidazo[4,5-C]quinoline compounds with a branched chain linking group for use as an immune response modifier
|
RU2020128440A
(ru)
|
2018-02-28 |
2022-03-28 |
Пфайзер Инк. |
Варианты il-15 и их применения
|
WO2019166937A1
(en)
|
2018-02-28 |
2019-09-06 |
3M Innovative Properties Company |
Substituted imidazo[4,5-c]quinoline compounds with an n-1 branched group
|
JP7384835B2
(ja)
|
2018-05-23 |
2023-11-21 |
ファイザー・インク |
Cd3に特異的な抗体及びその使用
|
TWI816396B
(zh)
|
2018-05-23 |
2023-09-21 |
美商輝瑞大藥廠 |
特異性針對gucy2c之抗體及其用途
|
EP3802536B1
(de)
|
2018-05-24 |
2022-07-13 |
3M Innovative Properties Company |
N-1 verzweigte cycloalkyl-substituierte imidazo[4,5-c]chinolinverbindungen, zusammensetzungen und verfahren
|
WO2020109898A1
(en)
|
2018-11-26 |
2020-06-04 |
3M Innovative Properties Company |
N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
|
WO2020128893A1
(en)
|
2018-12-21 |
2020-06-25 |
Pfizer Inc. |
Combination treatments of cancer comprising a tlr agonist
|
US20220177471A1
(en)
|
2019-06-06 |
2022-06-09 |
3M Innovative Properties Company |
N-1 branched alkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
|
EP3983408A1
(de)
|
2019-06-12 |
2022-04-20 |
3M Innovative Properties Company |
Phenethylsubstituierte imidazo[4,5-c]chinolin-verbindungen mit einer n-1-verzweigten gruppe
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
WO2021116420A1
(en)
|
2019-12-13 |
2021-06-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
|
EP4077387A1
(de)
|
2019-12-17 |
2022-10-26 |
Pfizer Inc. |
Antikörper mit spezifität für cd47, pd-l1 und verwendungen davon
|
WO2022009157A1
(en)
|
2020-07-10 |
2022-01-13 |
Novartis Ag |
Lhc165 and spartalizumab combinations for treating solid tumors
|
PE20231565A1
(es)
|
2020-07-17 |
2023-10-04 |
Pfizer |
Anticuerpos terapeuticos y sus usos
|